| Autor: |
Ban W.H Bdair, Satar J.R Algraittee, Hameed A Alhibaly, Abdulhamza R Hmood |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY. 12:46-50 |
| ISSN: |
0975-4415 |
| DOI: |
10.25258/ijddt.12.1.8 |
| Popis: |
The global burden of Type 2 diabetes mellitus (T2DM) is on the increase with over 500 million individuals of the world’s population being affected and diabetes associated deaths reaching over a million yearly. The progressiveness of the disease coupled with poor adherence to treatment requirements and lifestyle modifications T2DM very challenging as patients on single drug treatment may eventually require combination therapy up to the level of triple therapy without achieving euglycemia. In this study we hypothesize that the addition of pioglitazone as a fourth drug, may restore euglycemia and prevent the use of insulin. A total of 107 T2DM patients already on triple combination therapy were recruited and pioglitazone was introduced as a fourth drug in 66 patients (experimental group) while 41 patients served and as control. After 3 months, the mean post-treatment HbA1c in the experimental group was 7.00 ± 0.50% which showed statistically significant difference compared with the experimental group’s mean baseline HbA1c of 8.47 ± 0.51% at p is less than 0.05. Also, the mean post-treatment HbA1c of the experiment group showed statistically significant difference when compared with the post-treatment HbA1c of the control group at p is less than 0.05, i.e. 7.00 ± 0.50% (experimental group) vs. 8.55 ± 0.73% (control group). Our findings indicate that the addition of pioglitazone significantly improved the glycemic profile of the experimental subjects without necessitating the adoption of complex insulin-dependent strategies. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
